Biocon Limited, founded in 1978 by Kiran Mazumdar-Shaw, is India’s leading biopharmaceutical company, headquartered in Bengaluru. It focuses on developing affordable, innovative therapeutics for chronic diseases like diabetes, cancer, and autoimmune disorders. Biocon operates through four key segments: Generics (APIs and formulations), Biosimilars (insulin and monoclonal antibodies), Novel Biologics (new molecules), and Research Services (via subsidiary Syngene). Its business model emphasizes a fully integrated value chain, from drug discovery to commercialization, leveraging India’s cost-effective R&D and manufacturing capabilities.

With a global presence in over 120 countries, Biocon serves markets like the U.S., Europe, and emerging economies, though 86% of its demand comes from developed markets. The company has transitioned from API manufacturing to an innovation-led strategy, focusing on biosimilars and novel biologics to counter pricing pressures in generics. Strategic partnerships (e.g., Mylan, Viatris) and acquisitions (e.g., Viatris’ biosimilars business) have strengthened its global footprint. Biocon’s revenue for FY19 was ₹56,588 million (USD 871 million), with a market cap of approximately ₹33,568 crore in 2024. Despite challenges like regulatory complexities and competition, Biocon’s robust pipeline, cost advantage, and focus on health equity position it as a leader in India’s biotech revolution.